RxDoctor Payments Data

Allen Gee, MD

Neurology · Cody, WYNPI 1083793863

Payments from drug & device makers

What this record shows

43 manufacturers reported payments, led by Global Kinetics USA Corporation at 43.6% of the total. Reporting peaked in 2022 at $2,731 and has fallen 69.0% since, to $846 in 2025.

$7,575in general payments, 2019–2025

Across 220 payments — averaging $34.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Global Kinetics USA Corporation$3K
  • Bristol Myers Squibb$464
  • AbbVie$421
  • Biogen$405
  • Novartis$298
  • UCB, Inc.$248
  • plus $2K from 37 others
$420,556in research payments, 2019–2025

Across 2 payments — averaging $210,278 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biogen$421K

What the payments were for

  • Consulting fees$3,30044%
  • Food & beverage$4,27556%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neurology providers in Wyomingto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$2,824,695
Medicare patients
1,005
Services billed
72,162

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$101,158
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone34$7,996
Entacapone16$2,711
Oxcarbazepine15$1,710
Levetiracetam53$1,606
Gabapentin74$1,467
Baclofen65$1,312
Carbidopa-LevodopaCarbidopa/Levodopa29$1,185
Lacosamide15$1,075
Pregabalin73$970
Primidone39$915
Divalproex Sodium ErDivalproex Sodium11$670
Sumatriptan Succinate16$597
Tizanidine Hcl50$508
Ropinirole Hcl16$433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$147$101,15812 claims
Upsher-smith Laboratories LLCTopiramate$15$18913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neurology providers in Wyomingon file to place this against a meaningful peer group, so we don't.

Other neurology in Cody

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →